https://ourglp1.com/news/vct220-oral-glp1-phase-2-obesity-trialOurGLP1en2026-08-21T18:18:00+01:00VCT220 oral GLP-1: what its 16-week Phase II obesity trial found https://ourglp1.com/news/survodutide-synchronize1-phase-3-obesity-trialOurGLP1en2026-08-20T18:02:00+01:00Survodutide Phase 3: what the SYNCHRONIZE-1 obesity trial found